1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSCW
Ensysce Biosciences, Inc.US flagOther OTC
0.00
USD
+0.00
- -
16,902.00Market Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-29
-24
-11
-8
-10
-12
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
-7
-1
-4
-1
3
3
-1
LT Debt
- -
4
- -
- -
- -
- -
- -
Total Equity
-7
-8
-4
-1
3
3
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
5
9
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3
7
2
Cash, Cash Equivalents & STI
2
4
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
5
3
Payables & Accruals
2
4
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-149.11%
-14.65%
Free Cash Flow
- -
122.67%
5.69%
Net Income, GAAP
- -
-10,280.22%
27.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
D. Lynn Kirkpatrick
Full Time Employees
10
Sector
Healthcare
Industry
Biotechnology
Address
7946 Ivanhoe Avenue La Jolla CA United States of America 92037
IPO Date
Jun 30, 2021
CIK
0001716947
Website
ensysce.com
Similar Companies
Acasti Pharma Inc. (ACST)
Kidswell Bio Corporation (4584.T)
Regen BioPharma, Inc. (RGBP)
Veru Inc. (VERU)
Oncopeptides AB (publ) (ONCO.ST)
RespireRx Pharmaceuticals Inc. (RSPI)
Business
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc. (NASDAQ:ENSC) (ENSCW) is a clinical-stage biopharmaceutical company that develops proprietary prodrug technologies to create safer oral prescription medications for severe pain relief while minimizing risks of opioid misuse, abuse, and overdose. The company leverages its Trypsin Activated Abuse Protection (TAAP) platform, which employs a two-step activation mechanism requiring specific intestinal enzymes to prevent abuse via snorting, injection, chewing, or extraction; and its Multi-Pill Abuse Resistant (MPAR) platform, which incorporates a trypsin inhibitor like nafamostat to block overdose potential even if multiple pills are ingested orally. Its lead product candidate, PF614, is an extended-release oxycodone prodrug utilizing TAAP technology with FDA Fast Track and Breakthrough Therapy designations for treating severe pain; PF614-MPAR combines PF614 with MPAR for added oral overdose protection; and nafamostat is also advanced for potential use in treating infections and pulmonary diseases. Founded in 2003 and headquartered in La Jolla, California, Ensysce Biosciences operates primarily in the United States with a focus on the pain management and opioid crisis markets targeting patients, healthcare providers, and regulators concerned with prescription drug safety. In recent developments, the company announced a strategic partnership in December 2024 for the development and commercial launch of PF614 and PF614-MPAR; accelerated the PF614-MPAR-102 clinical study with full enrollment of Part 2; completed a $5 million financing round and secured a $14 million multi-year grant in 2024; received positive FDA feedback in November 2025 on the PF614 manufacturing approach; showcased its technologies at PAINWeek 2025 and the Pain Therapeutics Summit; and plans to submit a New Drug Application for PF614 by 2026 with commercialization targeted for year-end, subject to additional funding.